Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Reata Pharma (NQ: RETA ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Sep 25, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Reata Pharma < Previous 1 2 ... 7 8 9 10 11 12 13 14 Next > Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Reata Pharmaceuticals, Inc. (RETA) December 23, 2021 From Glancy Prongay & Murray LLP Via Business Wire REATA ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Reata Pharmaceuticals Inc. and Encourages Investors to Contact the Firm December 22, 2021 From Bragar Eagel & Squire, P.C. Via Business Wire Shareholder Action Notice: The Schall Law Firm Encourages Investors in Reata Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm December 22, 2021 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Topics Lawsuit Exposures Financial Legal EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Reata Pharmaceuticals, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – RETA December 22, 2021 From The Rosen Law Firm, P.A. Via Business Wire SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Reata Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm December 22, 2021 From The Schall Law Firm Via Business Wire Reata Deadline Alert December 21, 2021 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Reata Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm December 21, 2021 From The Schall Law Firm Via Business Wire ALERT: Reata Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RETA December 21, 2021 From Robbins Geller Rudman & Dowd LLP Via Business Wire The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Reata Pharmaceuticals, Inc. (RETA) Investors December 21, 2021 From The Law Offices of Frank R. Cruz Via Business Wire INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Reata Pharmaceuticals, Inc. (RETA) Investors December 20, 2021 From Law Offices of Howard G. Smith Via Business Wire RETA CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Reata Pharmaceuticals, Inc. December 20, 2021 From Glancy Prongay & Murray LLP Via Business Wire The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More December 12, 2021 Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple... Via Benzinga Exposures Product Safety REATA ALERT: Bragar Eagel & Squire, P.C. is Investigating Reata Pharmaceuticals, Inc. on Behalf of Reata Stockholders and Encourages Investors to Contact the Firm December 12, 2021 From Bragar Eagel & Squire, P.C. Via Business Wire The Law Offices of Frank R. Cruz Continues Its Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors December 10, 2021 From The Law Offices of Frank R. Cruz Via Business Wire 56 Biggest Movers From Yesterday December 10, 2021 Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares jumped 84% to close at $4.95 on Thursday after the company signed an exclusive summary distribution agreement... Via Benzinga Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors December 09, 2021 From Glancy Prongay & Murray LLP Via Business Wire INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of Reata Pharmaceuticals, Inc. (RETA) on Behalf of Investors December 09, 2021 From Law Offices of Howard G. Smith Via Business Wire Mid-Afternoon Market Update: Nasdaq Falls Over 1%; Reata Pharmaceuticals Shares Plummet December 09, 2021 Toward the end of trading Thursday, the Dow traded up 0.17% to 35,814.21 while the NASDAQ fell 1.13% to 15,608.30. The S&P also fell, dropping 0.28% to 4,688.20. The U.S. has... Via Benzinga Topics Stocks Exposures US Equities Looking At Reata Pharmaceuticals's Recent Whale Trades December 09, 2021 Someone with a lot of money to spend has taken a bearish stance on Reata Pharmaceuticals (NASDAQ:RETA). And retail traders should know. We noticed this today when the big position... Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session December 09, 2021 Gainers Ensysce Biosciences (NASDAQ:ENSC) shares increased by 88.08% to $5.61 during Thursday's regular session. As of 12:30 EST, Ensysce Biosciences's stock is... Via Benzinga Mid-Day Market Update: Crude Oil Down 1%; Inspira Technologies Shares Spike Higher December 09, 2021 Midway through trading Thursday, the Dow traded down 0.18% to 35,691.63 while the NASDAQ fell 0.72% to 15,672.75. The S&P also fell, dropping 0.37% to 4,683.86. The U.S. has... Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities 38 Stocks Moving In Thursday's Mid-Day Session December 09, 2021 Gainers Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) shares climbed 92.9% to $5.19 after the company signed an exclusive summary distribution agreement with Innovimed Sp... Via Benzinga Why Reata Pharmaceuticals Stock Got Absolutely Crushed on Thursday December 09, 2021 The biopharmaceutical company got some potentially devastating news from regulators. Via The Motley Fool Reata Pharmaceuticals Stock Nosedives On FDA Panel's Rejection Of Kidney Drug December 09, 2021 The vote was unanimous. Advisors said the evidence doesn't support the drug's merits. Via Investor's Business Daily Exposures Product Safety What 5 Analyst Ratings Have To Say About Reata Pharmaceuticals December 09, 2021 Over the past 3 months, 5 analysts have published their opinion on Reata Pharmaceuticals (NASDAQ: Via Benzinga Mid-Morning Market Update: Markets Open Lower; US Initial Jobless Claims Drop To 52-Year Low December 09, 2021 Following the market opening Thursday, the Dow traded down 0.22% to 35,676.45 while the NASDAQ fell 0.30% to 15,740.38. The S&P also fell, dropping 0.21% to 4,691.18. The U.S... Via Benzinga Topics Stocks Exposures US Equities Why Are Reata Pharmaceuticals Shares Plunging Premarket? December 09, 2021 The FDA's Cardiovascular and Renal Drugs Advisory Committee voted that the agency should not approve Reata Pharmaceuticals Inc's (NASDAQ: RETA) bardoxolone... Via Benzinga Exposures Product Safety Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021 December 09, 2021 Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ: Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session December 09, 2021 Gainers Ensysce Biosciences (NASDAQ:ENSC) stock increased by 74.49% to $5.2 during Thursday's pre-market session. The market value of their outstanding shares is at $... Via Benzinga The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO December 09, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug... Via Benzinga Exposures COVID-19 Product Safety < Previous 1 2 ... 7 8 9 10 11 12 13 14 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
